# Our Phase 3 ATTAIN-2 study demonstrated that an oral GLP-1 has the potential to achieve weight loss consistent with injectables in patients with both diabetes and obesity — a popul

**Zdroj:** [linkedin.com](https://www.linkedin.com/posts/danielskovronsky_our-phase-3-attain-2-study-demonstrated-that-activity-7366123120128081920-1Olh)
**Datum:** 2025-08-27

Agree & Join LinkedIn
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Chief Scientific Officer and President, Lilly Research Laboratories; President, Immunology at Eli Lilly and Company
Our Phase 3 ATTAIN-2 study demonstrated that an oral GLP-1 has the potential to achieve weight loss consistent with injectables in patients with both diabetes and obesity — a population where weight loss has historically been most challenging.